Circassia announces public offer for Aerocrine
UK biotech group Circassia Pharmaceuticals has made a public offer to acquire the Swedish medical technology company Aerocrine. The offer values all outstanding shares in Aerocrine at approximately SEK 1.78 billion.
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company developing a range of allergy treatments. The company’s share is listed on the London Stock Exchange. Aerocrine AB is a medical technology company focused on improving the treatment of patients with inflamed airways. The Aerocrine share is listed on Nasdaq Stockholm.
Aerocrine is being advised by Mannheimer Swartling in connection with the offer. The firm’s team includes Eva Hägg, Patrik Marcelius, Nils Nostell, Jessica Lindgren and Klara Wessman.